Dr. Reddy’s subsidiary Aurigene signs $438m licensing deal with Olema
Dr. Reddy’s Laboratories said that its fully-owned subsidiary Aurigene Discovery Technologies has signed an exclusive global collaboration and license agreement worth up to $438 million ... Read More
Olema Oncology to evaluate OP-1250, palbociclib combo in advanced breast cancer
Olema Oncology has entered into a clinical trial agreement with Pfizer to evaluate its small molecule OP-1250 in combination with the latter’s palbociclib (IBRANCE) in ... Read More